Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07070232
What this trial is testing

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Who this might be right for
Advanced Solid Tumor
BioNTech SE 1,438
Testing effectiveness (Phase 2)Active Not RecruitingNCT05585814
What this trial is testing

CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer

Who this might be right for
Locally Advanced Rectal Cancer
Shanghai Changzheng Hospital 30
Testing effectiveness (Phase 2)UnknownNCT03374293
What this trial is testing

Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Shixiu Wu 21
Testing effectiveness (Phase 2)Study completedNCT04900363
What this trial is testing

A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Akeso 108
Testing effectiveness (Phase 2)Study completedNCT04172506
What this trial is testing

Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors

Who this might be right for
Solid TumorLung CancerHCC
Akeso 65
Testing effectiveness (Phase 2)Looking for participantsNCT05886439
What this trial is testing

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

Who this might be right for
Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 60
Testing effectiveness (Phase 2)Study completedNCT04068519
What this trial is testing

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

Who this might be right for
Advanced Solid Tumors
BeiGene 300
Early research (Phase 1)Not Yet RecruitingNCT07318636
What this trial is testing

NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC

Who this might be right for
Resectable Non-small Cell Lung Cancer
The First Affiliated Hospital of Guangzhou Medical University 10
Testing effectiveness (Phase 2)Looking for participantsNCT05766800
What this trial is testing

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

Who this might be right for
Locally AdvancedNon-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 100
Testing effectiveness (Phase 2)Looking for participantsNCT07131202
What this trial is testing

FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Suzhou Forlong Biotechnology Co., Ltd 130
Testing effectiveness (Phase 2)Study completedNCT04380805
What this trial is testing

AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer

Who this might be right for
Recurrent Cervical CancerMetastatic Cervical Cancer
Akeso 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05518994
What this trial is testing

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma

Who this might be right for
Astrocytoma of Brain
Henan Provincial People's Hospital 70
Early research (Phase 1)UnknownNCT05370755
What this trial is testing

ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

Who this might be right for
Patients With Advanced Solid Tumors
Beijing InnoCare Pharma Tech Co., Ltd. 22
Testing effectiveness (Phase 2)Study completedNCT02899793
What this trial is testing

Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

Who this might be right for
Recurrent Endometrial Cancer
Yale University 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT04825938
What this trial is testing

Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Who this might be right for
Salivary Gland Malignant NeoplasmsSalivary Gland Tumors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 15
Testing effectiveness (Phase 2)UnknownNCT04989855
What this trial is testing

Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score

Who this might be right for
Locally Advanced Rectal Cancer
Sun Yat-sen University 48
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06014944
What this trial is testing

Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody

Who this might be right for
Rectal Cancer
Changhai Hospital 30
Early research (Phase 1)UnknownNCT04756934
What this trial is testing

HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma

Who this might be right for
Melanoma
Taizhou HoudeAoke Biomedical Co., Ltd. 63
Testing effectiveness (Phase 2)UnknownNCT04635956
What this trial is testing

Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas

Who this might be right for
ChemotherapyAnti-pd-1 AntibodyCervical Neuroendocrine Carcinoma+4 more
Lei Li 20
Large-scale testing (Phase 3)Looking for participantsNCT05582265
What this trial is testing

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

Who this might be right for
Head and Neck Squamous Cell Carcinomas
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 537
Next Page